PMCB · PharmaCyte Biotech Inc
United States · RS rating 12 · As of 2026-11-03
| Price | 0.34 USD |
|---|---|
| 1-day change | +9.6% |
| RS rating (overall / 1M / 3M / 12M) | 12 / 30 / 12 / 15 |
| Stage | Declining |
| Composite / Minervini / CANSLIM score | 24 / 9 / 37 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | +86.3% |
| Sales growth Q/Q | – |
| Distance from 52-week high | +72.1% |
| Market cap (USD) | $8.1M |